Table III.
Biochemical and Imaging Characteristics before and after Neoadjuvant Therapy
Pre-GTX/IMRT | Post-GTX/IMRT | p-value | ||
---|---|---|---|---|
Median CA 19-9 (units/mL) | 483 | 50 | <0.01 | * |
Range | 0–9590 | 0–5450 | ||
Median PET SUV max | 5.7 | 1.6 | <0.001 | # |
Range | 3.4–13.9 | 0–4 | ||
Median Pancreatic Mass Size by CT (cm) | 3.35 | 2.70 | 0.002 | |
Range | 2.0–5.0 | 0–5.0 |
8/16 patients had a > 85% decrease in CA 19-9 levels
7/14 patients had a 100% decrease in PET SUV max